New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ame- liorates proteinuria. Nephrol Dial Transplant. 2011;26(10):3237-3342.Smerud HK, Barany P, Lindstrom K, et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ...
AIMS: IgA nephropathy (IgAN) is the most frequent glomerulonephritis around the globe, but its incidence in the United States is unknown. The disease has a preponderance for certain racial/ethnic groups. Our goals were to retrospectively analyze a series of IgAN biopsies from the state of New ...
Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) announced today that the Singapore Health Sciences Authority (HSA) has accepted its New Drug Application (NDA) for Nefecon for the treatment of primary immunoglobulin A neph...
“We are excited that Nefecon®, the world’s first treatment for IgA nephropathy approved by the U.S. FDA and EU EMA and the leading product in our renal portfolio, will soon be accessible to IgAN patients...
doi:10.1142/9789811286049_0010The following sections are included:IntroductionPathogenesisTherapiesConclusionReferences#Introduction#Pathogenesis#Therapies#Conclusion#ReferencesCOMPREHENSIVE FRONTIER OF KIDNEY DISEASELing-Yun LaiDepartment of Nephrology, Huashan Hospital affiliated to Fudan University, Shanghai, China...
Previously approved medications that have gained new FDA approval for the treatment of additional medical conditions.
home / peers-and-perspective / preparing-for-a-new-era-in-igan-treatment-staying-up-to-date-on-the-latest-developments-in Experts in nephrology take a deep dive into the latest developments in immune-modulating therapies in IgA (immunoglobulin A) nephropathy. Th...
预售 按需印刷 New Insights into the Pathogenesis and Therapies of IgA Nephropathy563.4 元 去天猫购买声明:此商品数据来源由淘宝官方接口提供,所有交易过程在淘宝或天猫与第三方卖家进行,本网站不参与交易,如有交易产生的疑问请联系天猫卖家【中图数字图书专营店】,如需删除此页面请 联系本站 >> ...
Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch-Schonlein purpura nephritisDelangheS.E.SpeeckaertM.M.SegersH.DesmetK.ingentaconnectClinical Biochemistry Ottawa Then New York Pergamon Press Elsevier Science
Major advances in the treatment of ANCA associated-renal vasculitides, IGA nephropathy and renal autosomal dominant polycystic disease were published within the past year. There is neither clear benefit of early initiation of renal replacement therapy in the intensive care unit nor with the use of ch...